Jul, 11 2019 13:59 JST

Source: Eisai

Eisai Listed for 18th Consecutive Year in FTSE4Good Index Series

An Index for Socially Responsible Investment
Eisai

TOKYO, Jul, 11 2019 - (JCN Newswire) - Eisai Co., Ltd. announced today that it has been included in the FTSE4Good Index Series for the 18th consecutive year since its initial inclusion in 2002.

The FTSE4Good Index Series is a global index series for socially responsible investment.

The FTSE4Good Index Series is designed to help investors integrate the global standard factors of environmental, social and governance (ESG) into their investment decisions. Eisai received particularly high scores in "Customer Responsibility", "Labor Standards", "Corporate governance", "Anti-Corruption", and "Climate Change", among others. As of July 2019, a total of 1,034 companies from around the world have been selected for the FTSE4Good Developed Index, including 175 companies from Japan.

Along with being listed in the FTSE4Good Index Series, Eisai is also listed in the MSCI Japan Empowering Women Index (WIN), the FTSE Blossom Japan Index, the MSCI Japan ESG Select Leaders Index, and S&P/JPX Carbon Efficient Index, which are the four ESG investment indices for Japanese stocks adopted by the Government Pension Investment Fund (GPIF).

Eisai's corporate philosophy is to give first thought to patients and their families, and increase the benefits that health care provides as well as address diverse healthcare needs worldwide. By strengthening its ESG initiatives and increasing non-financial value, Eisai is striving to sustainably enhance corporate value based on this corporate philosophy.


About Eisai
Eisai Co., Ltd. is a leading global research and development-based pharmaceutical company headquartered in Japan. We define our corporate mission as "giving first thought to patients and their families and to increasing the benefits health care provides," which we call our human health care (hhc) philosophy. With approximately 10,000 employees working across our global network of R&D facilities, manufacturing sites and marketing subsidiaries, we strive to realize our hhc philosophy by delivering innovative products in various therapeutic areas with high unmet medical needs, including Neurology and Oncology.

Furthermore, we invest and participate in several partnership-based initiatives to improve access to medicines in developing and emerging countries.

For more information about Eisai Co., Ltd., please visit www.eisai.com


Contact:
Media Inquiries:
Public Relations Department,
Eisai Co., Ltd.
+81-(0)3-3817-5120
Source: Eisai
Sectors: BioTech

Copyright ©2019 JCN Newswire. All rights reserved. A division of Japan Corporate News Network.

Related Press Release


Eisai Receives Iia Japan Chairman's Award of Institute of Internal Auditors - Japan
September 17 2019 15:42 JST
 
Eisai and Biogen to Discontinue Phase III Clinical Studies of Bace Inhibitor Elenbecestat in Early Alzheimer's Disease
September 13 2019 17:43 JST
 
Eisai to Launch New "Etak Antimicrobial Wet Wipes" With One Week Lasting Antimicrobial Action
August 29 2019 10:46 JST
 
Eisai Enters Into Business Alliance With Cogstate for Exclusive Development and Commercialization of a Digital Tool for Self-Assessment of Cognitive Function in Japan
August 28 2019 09:58 JST
 
Eisai Provides Tanks to Supply Clean Water to Neglected Tropical Diseases Endemic Regions in Kenya, in Collaboration With Merck
August 27 2019 11:37 JST
 
Eisai to Refresh and Launch Sahne Cream After 20 Years with Mild Scent and New Package
August 01 2019 10:41 JST
 
Eisai and Merck & Co., Inc., Kenilworth, N.J., U.S.A. Receive Breakthrough Therapy Designation from FDA
July 23 2019 11:37 JST
 
Eisai Presented Latest Trends of Treatment for Alzheimer's at AAIC 2019
July 19 2019 12:00 JST
 
Eisai Presented Data Showing Quantification of Tau Microtubule Binding Region at AAIC 2019
July 19 2019 08:15 JST
 
Eisai Presents Research Evaluating Correlation of Highly-Precisely Measured Amyloid Beta in Plasma and Cerebrospinal Fluid with Newly Developed Automated Protein Assay System at AAIC 2019
July 18 2019 13:26 JST
 
More Press release >>

Latest Press Release


More Latest Release >>